NVO•benzinga•
Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detai
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga